JP2011523849A5 - - Google Patents

Download PDF

Info

Publication number
JP2011523849A5
JP2011523849A5 JP2011510744A JP2011510744A JP2011523849A5 JP 2011523849 A5 JP2011523849 A5 JP 2011523849A5 JP 2011510744 A JP2011510744 A JP 2011510744A JP 2011510744 A JP2011510744 A JP 2011510744A JP 2011523849 A5 JP2011523849 A5 JP 2011523849A5
Authority
JP
Japan
Prior art keywords
antigen
binding protein
binding
binding fragment
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011510744A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011523849A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/045182 external-priority patent/WO2009143523A1/en
Publication of JP2011523849A publication Critical patent/JP2011523849A/ja
Publication of JP2011523849A5 publication Critical patent/JP2011523849A5/ja
Pending legal-status Critical Current

Links

JP2011510744A 2008-05-23 2009-05-26 インターロイキン−21受容体結合性タンパク質 Pending JP2011523849A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5550008P 2008-05-23 2008-05-23
US61/055,500 2008-05-23
PCT/US2009/045182 WO2009143523A1 (en) 2008-05-23 2009-05-26 Interleukin-21 receptor binding proteins

Publications (2)

Publication Number Publication Date
JP2011523849A JP2011523849A (ja) 2011-08-25
JP2011523849A5 true JP2011523849A5 (https=) 2012-07-12

Family

ID=41112652

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011510744A Pending JP2011523849A (ja) 2008-05-23 2009-05-26 インターロイキン−21受容体結合性タンパク質

Country Status (20)

Country Link
US (2) US8163884B2 (https=)
EP (1) EP2297199A1 (https=)
JP (1) JP2011523849A (https=)
KR (1) KR20110040773A (https=)
CN (1) CN102105491A (https=)
AR (1) AR071885A1 (https=)
AU (1) AU2009248809A1 (https=)
CA (1) CA2724915A1 (https=)
CL (1) CL2009001284A1 (https=)
CO (1) CO6382184A2 (https=)
IL (1) IL209328A0 (https=)
MX (1) MX2010012811A (https=)
MY (1) MY149448A (https=)
NZ (1) NZ589330A (https=)
PE (1) PE20100141A1 (https=)
RU (1) RU2010152690A (https=)
SA (1) SA109300315B1 (https=)
TW (1) TW201000129A (https=)
WO (1) WO2009143523A1 (https=)
ZA (1) ZA201008335B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057128A (en) 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
CA2785678C (en) * 2009-12-25 2018-12-18 Sekisui Medical Co., Ltd. Human insulin assay and assay reagent
ES2628841T3 (es) * 2010-03-12 2017-08-04 Alexion Pharmaceuticals, Inc. Proteínas de fusión npp1
US9309318B2 (en) * 2012-10-17 2016-04-12 Amgen, Inc. Compositions relating to anti-IL-21 receptor antibodies
US20190185559A1 (en) * 2016-09-02 2019-06-20 The Brigham And Women's Hospital, Inc. Compositions and methods for treating neoplasias
EP3687565A1 (en) 2017-09-27 2020-08-05 Alexion Pharmaceuticals, Inc. Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (npp1)
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057128A (en) * 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
US7198789B2 (en) * 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US7189400B2 (en) * 1998-03-17 2007-03-13 Genetics Institute, Llc Methods of treatment with antagonists of MU-1
US6576744B1 (en) * 1998-09-23 2003-06-10 Zymogenetics, Inc. Cytokine receptor zalpha11
EP1881070B1 (en) 1999-03-09 2012-10-03 Zymogenetics, Inc. Human cytokine as ligand of the zalpha receptor and uses thereof
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
WO2000069880A1 (en) 1999-05-18 2000-11-23 Millennium Pharmaceuticals, Inc. Il-9/il-2 receptor-like molecules and uses thereof
ES2279809T3 (es) * 2000-04-05 2007-09-01 Zymogenetics, Inc. Receptores de citoquina zalfa11 solubles.
ES2276795T3 (es) 2000-05-11 2007-07-01 Genetics Institute, Llc Mu-1, miembro de la familia del receptor de citoquina.
DK1451322T3 (da) * 2001-11-05 2010-02-01 Zymogenetics Inc Il-21-antagonister
US20040016010A1 (en) * 2002-04-17 2004-01-22 Marion Kasaian IL-21 receptor knockout animal and methods of use thereof
MXPA04012116A (es) * 2002-06-07 2005-04-19 Zymogenetics Inc Uso del il-21 en cancer y otras aplicaciones terapeuticas.
CN1688340A (zh) * 2002-07-15 2005-10-26 韦思公司 调节t辅助(th)细胞发育和功能的方法和组合物
CA2518371A1 (en) * 2003-03-14 2004-09-30 Wyeth Antibodies against human il-21 receptor and uses therefor
KR20060015482A (ko) * 2003-03-21 2006-02-17 와이어쓰 인터루킨-21/인터루킨-21 수용체의 작용제를 이용한면역장애의 치료
US7276478B2 (en) * 2003-09-25 2007-10-02 Zymogenetics, Inc. Methods of treating autoimmune diseases using IL-21
US20060024268A1 (en) * 2004-05-19 2006-02-02 Wyeth Modulation of immunoglobulin production and atopic disorders
CN101052419A (zh) * 2004-08-05 2007-10-10 惠氏公司 拮抗白介素-21受体活性
CA2574848A1 (en) * 2004-08-05 2006-12-21 Wyeth Antagonizing interleukin-21 receptor activity
GT200600148A (es) * 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
WO2008081198A1 (en) 2007-01-05 2008-07-10 Imperial Innovations Ltd Blood assays for predicting inflammatory responses

Similar Documents

Publication Publication Date Title
JP2011523849A5 (https=)
JP2011520989A5 (https=)
JP2009531023A5 (https=)
JP2022061992A5 (https=)
JP2020023523A5 (https=)
JP2011508592A5 (https=)
JP2008542278A5 (https=)
JP2012501670A5 (https=)
JP2014521313A5 (https=)
JP2016501839A5 (https=)
JP2006523711A5 (https=)
JP2010524489A5 (https=)
JP2012010714A5 (https=)
CN105358175B (zh) 用于治疗硬皮病的抗ccl2和抗loxl2组合疗法
JP2010511388A5 (https=)
JP2010529860A5 (https=)
JP2021501744A5 (https=)
JP2014509187A5 (https=)
JP2013519364A5 (https=)
HRP20151227T1 (hr) Sastavi i postupci uporabe za terapeutska protutijela
JP2012504401A5 (https=)
JP2009225799A5 (https=)
JP2015535691A5 (https=)
JP2012524524A5 (https=)
JP2012070740A5 (https=)